Pulmonx is a medical devices business based in the US. Pulmonx shares (LUNG) are listed on the NASDAQ and all prices are listed in US Dollars. Pulmonx employs 279 staff and has a trailing 12-month revenue of around $73 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.84 |
|---|---|
| 52-week range | $5.67 - $14.84 |
| 50-day moving average | $7.29 |
| 200-day moving average | $9.72 |
| Wall St. target price | $14.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.54 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.84 from 2024-07-25
| 1 week (2024-07-19) | -1.01% |
|---|---|
| 1 month (2024-06-27) | 27.07% |
| 3 months (2024-04-26) | 7.69% |
| 6 months (2024-01-26) | -41.49% |
| 1 year (2023-07-27) | -39.37% |
|---|---|
| 2 years (2022-07-27) | -52.51% |
| 3 years (2021-07-27) | 38.49 |
| 5 years (2019-07-23) | N/A |
| Revenue TTM | $73 million |
|---|---|
| Gross profit TTM | $39.9 million |
| Return on assets TTM | -20.52% |
| Return on equity TTM | -46.17% |
| Profit margin | -80.46% |
| Book value | $2.85 |
| Market Capitalization | $307.4 million |
TTM: trailing 12 months
We're not expecting Pulmonx to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Pulmonx's shares have ranged in value from as little as $5.67 up to $14.835. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulmonx's is 0.624. This would suggest that Pulmonx's shares are less volatile than average (for this exchange).
To put Pulmonx's beta into context you can compare it against those of similar companies.
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. .
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.